Synthesis and Biological Evaluation of 1,4-Naphthoquinone-1,2,3-triazole Hybrids as Potential Antivenom Agents against Bothrops spp. Snake Venoms
ACS Omega · 16.11.2026
DOI: 10.1021/acsomega.6c09242 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 16.11.2026. Verfasst von Andresa N. de Lima Silva und 9 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico, Funda??o Carlos Chagas Filho de Amparo ? Pesquisa do Estado do Rio de Janeiro, Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior.
Abstract (Originalsprache)
Snakebite envenomation is a neglected tropical disease associated with substantial morbidity and mortality worldwide, highlighting the need for complementary approaches to conventional antivenom therapy. Herein, 12 1,4-naphthoquinone-1,2,3-triazole hybrids (6a–l) were investigated for their ability to inhibit toxic activities induced by the venoms of Bothrops jararaca and B. jararacussu. The compounds were obtained through an ultrasound-assisted copper-catalyzed azide–alkyne cycloaddition (CuAAC) between 2-(azidomethyl)-3-methylnaphthalene-1,4-dione (4) and terminal alkynes (5), affording the derivatives in 54–92% yields. Their effects on venom proteolytic, coagulant, and phospholipase A2 (PLA2) activities were evaluated after incubation with the venoms for 30 min at 37 °C. In addition, in silico ADME and toxicity analyses were performed to assess their physicochemical and pharmacokinetic properties. All compounds complied with Lipinski’s rule of five, although low predicted aqueous solubility was observed for some derivatives and a toxicity alert was identified for 6k. In vitro assays showed that most compounds inhibited venom proteolytic activity by 30–90%, with distinct responses depending on the venom species. Notably, 6i showed no inhibition against B. jararaca venom but reduced proteolytic activity of B. jararacussu by approximately 60%. Compounds 6c, 6g, and 6i also displayed selective inhibition of venom-induced fibrinogen coagulation. Regarding PLA2 activity, 6a completely inhibited the activity of B. jararaca venom, while 6b and 6h produced approximately 92% inhibition; against B. jararacussu, measurable inhibition was observed for 6a, 6e, and 6f. Overall, the results reveal compounds- and venom species-dependent inhibitory profiles and provide biological evidence supporting further investigation of 1,4-naphthoquinone-1,2,3-triazole hybrids as potential scaffolds for complementary approaches to snakebite envenomation.
Förderung
- Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
- Funda??o Carlos Chagas Filho de Amparo ? Pesquisa do Estado do Rio de Janeiro
- Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior
Zitieren
APA
Silva, A. N. D. L., Andrade, I. M. G., Ribeiro, R. C. B., Oliveira, B. B. D., Desmarais, M. D. O. L., Sanchez, E. F., Ferreira, V. F., Forezi, L. D. S. M., Fuly, A. L., & Silva, F. D. C. D. (2026). Synthesis and Biological Evaluation of 1,4-Naphthoquinone-1,2,3-triazole Hybrids as Potential Antivenom Agents against Bothrops spp. Snake Venoms. ACS Omega. https://doi.org/10.1021/acsomega.6c09242
Vancouver
Silva ANDL, Andrade IMG, Ribeiro RCB, Oliveira BBD, Desmarais MDOL, Sanchez EF, et al. Synthesis and Biological Evaluation of 1,4-Naphthoquinone-1,2,3-triazole Hybrids as Potential Antivenom Agents against Bothrops spp. Snake Venoms. ACS Omega. 2026. doi:10.1021/acsomega.6c09242
BibTeX
@article{Silva2026,
author = {Silva, Andresa N. de Lima and Andrade, Isadora M. G. and Ribeiro, Ruan C. B. and Oliveira, Brenda B. de and Desmarais, Mariana de Oliveira Leal and Sanchez, Eladio F. and Ferreira, Vitor F. and Forezi, Luana da Silva Magalhães and Fuly, André L. and Silva, Fernando de Carvalho da},
title = {Synthesis and Biological Evaluation of 1,4-Naphthoquinone-1,2,3-triazole Hybrids as Potential Antivenom Agents against Bothrops spp. Snake Venoms},
journal = {ACS Omega},
year = {2026},
doi = {10.1021/acsomega.6c09242}
}
EUVIMED